Why the study?
Does low-dose prasugrel reduce ischemic events or increase bleeding compared to standard-dose clopidogrel in East Asian patients with acute coronary syndrome undergoing PCI?
Does low-dose prasugrel reduce ischemic events or increase bleeding compared to standard-dose clopidogrel in East Asian patients with acute coronary syndrome undergoing PCI?
In East Asian patients with acute coronary syndrome undergoing PCI, low-dose prasugrel is associated with higher bleeding risk without a reduction in ischemic events compared to standard-dose clopidogrel.
Answers are grounded in this paper and cite their sources.
Higher bleeding without ischemic benefit with low-dose prasugrel in East Asian ACS-PCI patients should not yet change practice; leaves open optimal P2Y12 selection.
Since its approval, low-dose prasugrel has been used by nearly 80% of patients who undergo PCI. Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups. These results suggest the importance of a risk assessment of bleeding prior to selecting a P2Y12 inhibitor, even for the use of a lower approved dose, when treating patients of East Asian descent.
No takes yet. Share an insight, caveat, or question.
Shoji et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: